154 related articles for article (PubMed ID: 1374065)
1. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.
Zagars GK
Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
Zagars GK; von Eschenbach AC
Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy.
Fijuth J; Chauvet B; Vincent P; Félix-Faure C; Reboul F
Radiother Oncol; 1992 Apr; 23(4):236-40. PubMed ID: 1376935
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
Zagars GK; Sherman NE; Babaian RJ
Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
Kavadi VS; Zagars GK; Pollack A
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
9. External beam radiotherapy dose response of prostate cancer.
Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1011-8. PubMed ID: 9392538
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate.
Zagars GK
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):39-45. PubMed ID: 7690017
[TBL] [Abstract][Full Text] [Related]
11. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment.
Zagars GK; Pollack A
Radiother Oncol; 1994 Feb; 30(2):121-7. PubMed ID: 7514308
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
13. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
[TBL] [Abstract][Full Text] [Related]
15. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
Zagars GK; Pollack A; Smith LG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
[TBL] [Abstract][Full Text] [Related]
16. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Pollack A; Zagars GK; Kavadi VS
Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
[TBL] [Abstract][Full Text] [Related]
18. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
Lattanzi JP; Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
[TBL] [Abstract][Full Text] [Related]
19. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
